Login to Your Account

Other News To Note

Friday, September 30, 2011
CorMedix Inc., of Bridgewater, N.J., is requesting a pre-investigational new drug meeting with the FDA to discuss next steps for Neutrolin, which is being developed for the prevention of catheter-related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription